OTCMKTS:INNVD Innovus Pharmaceuticals (INNVD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Innovus Pharmaceuticals Stock (OTCMKTS:INNVD) Get INNVD alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume4,300 shsAverage Volume9,592 shsMarket Capitalization$7.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovus Pharmaceuticals, Inc. was a San Diego-based healthcare company focused on developing, commercializing and distributing pharmaceutical and consumer-health products. Its portfolio addressed areas including men’s and women’s health, sexual wellness, prostate health, respiratory care, pain management and general wellness. The company marketed products under brands such as Zestra, EjectDelay, Sensum+, Vesele and UriVarx, along with dietary supplements and other over-the-counter offerings. Innovus generally pursued products that could be sold through retail, direct-to-consumer and healthcare-related distribution channels rather than relying solely on traditional drug development. Innovus served customers in the United States and select international markets through distribution and commercial partnerships. The company was acquired by Aytu BioPharma in 2020, after which Innovus operated as part of Aytu’s broader healthcare-products business.AI Generated. May Contain Errors. Read More Receive INNVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INNVD Stock News HeadlinesTarsus Pharmaceuticals: Undervalued Growth Potential with Strong Sales Performance and Strategic Market ExpansionNovember 14, 2024 | markets.businessinsider.comCorvus Pharmaceuticals’ Soquelitinib: Optimism and Market Potential Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 5 at 1:00 AM | Weiss Ratings (Ad)Corvus Unveils Data On Ciforadenant's Potential To Overcome Immunotherapy Resistance In MCRPCNovember 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)October 8, 2024 | markets.businessinsider.comThe Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 ExpertsOctober 4, 2024 | benzinga.comINmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On GoalSeptember 30, 2024 | seekingalpha.comNivagen Pharmaceuticals Sells MedisourceRx Business Unit to Leading Health & Wellness CompanySeptember 24, 2024 | businesswire.comSee More Headlines INNVD Stock Analysis - Frequently Asked Questions How were Innovus Pharmaceuticals' earnings last quarter? Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) posted its quarterly earnings data on Monday, April, 1st. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.12. The company had revenue of $4.75 million for the quarter, compared to analyst estimates of $8.13 million. Innovus Pharmaceuticals had a negative net margin of 34.51% and a negative trailing twelve-month return on equity of 682.54%. How do I buy shares of Innovus Pharmaceuticals? Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/01/2019Today10/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:INNVD CIKN/A Webwww.innovuspharma.com Phone858-964-5123FaxN/AEmployees12Year Founded2011Profitability EPS (Trailing Twelve Months)($4.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.28 million Net Margins-34.51% Pretax MarginN/A Return on Equity-682.54% Return on Assets-78.57% Debt Debt-to-Equity RatioN/A Current Ratio0.68 Quick Ratio0.36 Sales & Book Value Annual Sales$23.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / BookN/AMiscellaneous Outstanding Shares2,356,000Free FloatN/AMarket Cap$7.07 million OptionableNot Optionable Beta2.89 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:INNVD) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
